In a FiercePharma story today, it was reported that:
The FTC suied Abbot Laboratories and Teva Pharmaceuticals for allegedly striking a deal to keep an AndroGel copycat off the market.
But, in all honesty, is anyone really surprised?
I didn’t think so. As you may recall, the FTC has gone after AstraZeneca, Ranbaxy and Endo Pharma with “pay-for-delay” challenges.
What I find really interesting in all of this is I haven’t heard the drug manufacturers (neither the brands nor generics) discuss their development of medications for the patients – who are the ones buying them and taking them! As usual, the focus is on the financial component, which is critical – but not singular. Treating people with diseases is complex, and while it’s definitely a business, often times the patients, and even clinicians are left behind.
So, what could the FTC focus on? How about finding out if patients really want or feel they need a generic brand of a drug? How about asking clinicians if they want or feel the need to prescribe a specific type of drug? Getting straight to the heart of the matter that way make result on the “pay-for-delay” discussions being replaced by “need and desire for” discussions.